alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
[Federal Register Volume 89, Number 22 (Thursday, February 1, 2024)]
[Notices]
[Page 6527]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-01954]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Allergy and Infectious Diseases; Notice of 
Closed Meeting

    Pursuant to section 1009 of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The contract proposals and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the contract proposals, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Allergy and Infectious 
Diseases Special Emphasis Panel; HHS-NIH-CDC-SBIR PHS 2024-1 Phase I 
and Phase II: Reagents for Immunologic Analysis of Non-mammalian and 
Underrepresented Mammalian Models (Topic 129).
    Date: February 26-29, 2024.
    Time: 9:30 a.m. to 6:00 p.m.
    Agenda: To review and evaluate contract proposals.
    Place: National Institute of Allergy and Infectious Diseases, 
National Institutes of Health, 5601 Fishers Lane, Room 3G56, 
Rockville, MD 20892 (Video Assisted Meeting).
    Contact Person: Poonam Tewary, Ph.D., Scientific Review Officer, 
Scientific Review Program, Division of Extramural Activities, 
National Institute of Allergy and Infectious Diseases, National 
Institutes of Health, 5601 Fishers Lane, Room 3G56, Rockville, MD 
20852, (301) 761-7219, <a href="/cdn-cgi/l/email-protection#bdc9d8cadccfc4cdfdd0dcd4d193d3d4d593dad2cb"><span class="__cf_email__" data-cfemail="6511001204171c152508040c094b0b0c0d4b020a13">[email protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, 
Allergy, Immunology, and Transplantation Research; 93.856, 
Microbiology and Infectious Diseases Research, National Institutes 
of Health, HHS)

    Dated: January 26, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-01954 Filed 1-31-24; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
_______________________________________ __ Michigan Supreme Court 

# Order

Lansing, Michigan

February 9, 2007 Clifford W. Taylor, Chief Justice

Michael F. Cavanagh
Elizabeth A. Weaver 132991 & (19)(20) Marilyn Kelly Maura D. Corrigan Robert P. Young, Jr. Stephen J. Markman, GRAND RAPIDS EDUC ATIONAL SUPPORT Justices PERSONNEL ASSOCIATION, MEA/NEA Plaintiffs-Appellees,

v SC: 132991 COA: 272267 Kent CC: 05-004837-CZ DEAN TRANSPORTATI ON, INC., and DEAN MANAGEMENT SERVICES, INC., Defendants-Appellants.

________________ _______________ __________/

On order of the Chief Justice, a sti pulation signed by counsel for the parties agreeing to the dismissal of this application for leave to appeal is considered, and the application for leave to appeal is DISMISSED with prej udice and without costs. The
motions for immediate consideration and for stay of proceedings are DENIED as moot.

d0206 I, Corbin R. Davis, Clerk of the Mi chigan Supreme Cour t, certify that the foregoing is a true and complete copy of the order entered at the direction of the Court.

February 9, 2007

Clerk
#### UNITED STATES of America, Plaintiff-Appellee, v. Lazaro ROMAN, Defendant-Appellant.

No. 90-9084.

United States Court of Appeals, Eleventh Circuit.

July 28, 1992.

Hulane E. George, Milledgeville, Ga. (court-appointed), for defendant-appellant.

Michael T. Solis, George F. Peterman, III, Asst. U.S. Attys., Macon, Ga., Thomas M. Gannon, Appellate Section, Crim. Div., Dept, of Justice, Washington, D.C., for plaintiff-appellee.

ON PETITION FOR REHEARING AND SUGGESTION FOR REHEARING EN BANC

(Opinion May 7, 1992, 11th Cir., 1992, 960 F.2d 130)

Before TJOFLAT, Chief Judge, FAY, KRAVITCH, HATCHETT, ANDERSON, EDMONDSON, COX, BIRCH and DUBINA, Circuit Judges.

BY THE COURT:

A member of this court in active service having requested a poll on the application for rehearing en banc and a majority of the judges in this court in active service having voted in favor of granting a rehearing en banc,

IT IS ORDERED that the above cause shall be reheard by this court en banc. The previous panel’s opinion is hereby VACATED.
**Exhibit 31.1**

 

**CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER**

 

I,Michael N. Chang, certify that:

 

1.I have reviewed this quarterly report on Form 10-Q of Optimer Pharmaceuticals,Inc.;

 

2.Based on my knowledge, this report does not contain any untrue statement of amaterial fact or omit to state a material fact necessary to make the statementsmade, in light of the circumstances under which such statements were made, notmisleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financialinformation included in this report, fairly present in all material respectsthe financial condition, results of operations and cash flows of the registrantas of, and for, the periods presented in this report;

 

4.The registrant’s other certifying officer and I are responsible forestablishing and maintaining disclosure controls and procedures (as defined inExchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

 

a)         designed such disclosure controls andprocedures, or caused such disclosure controls and procedures to be designedunder our supervision, to ensure that material information relating to theregistrant, including any consolidated subsidiaries, is made known to us byothers within those entities, particularly during the period in which thisreport is being prepared;

 

b)        evaluated the effectiveness of the registrant’sdisclosure controls and procedures and presented in this report our conclusionsabout the effectiveness of the disclosure controls and procedures, as of theend of the period covered by this report based on such evaluation; and

 

c)         disclosed in this report any change in theregistrant’s internal control over financial reporting that occurred during theregistrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarterin the case of an annual report) that has materially affected, or is reasonablylikely to materially affect, the registrant’s internal control over financialreporting; and

 

5.The registrant’s other certifying officer and I have disclosed, based on ourmost recent evaluation of internal control over financial reporting, to theregistrant’s auditors and the audit committee of the registrant’s board ofdirectors (or persons performing the equivalent functions):

 

a)         all significant deficiencies andmaterial weaknesses in the design or operation of internal control overfinancial reporting which are reasonably likely to adversely affect theregistrant’s ability to record, process, summarize and report financialinformation; and

 

b)        any fraud, whether or not material, thatinvolves management or other employees who have a significant role in theregistrant’s internal control over financial reporting.

 

 

Date:November 9, 2007 

 
| /s/ Michael N. Chang                   |   |
|----------------------------------------|--------|
| Michael  N. Chang                      |   |
| President  and Chief Executive Officer |   |

 

----
Exhibit 32.2
 CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO RULE 13a-14(b) OR RULE 15d-14(b)
OF THE SECURITIES EXCHANGE ACT OF 1934
AND 18 U.S.C. SECTION 1350
  Date:  August 7, 2008
    /s/ Charles F. CargileCharles F. CargileSenior Vice President, Chief Financial Officer
and Treasurer
(Principal Financial Officer)
##### 



Exhibit 32.2 Certification of the Chief Financial Officer
Pursuant to 18 U.S.C. Section 1350,
As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Quarterly Report of Accenture SCA (the Company) on Form 10-Q for
the period ended November 30, 2004 as filed with the Securities and Exchange Commission on the date
hereof (the Report), I, Michael G. McGrath, Chief Financial Officer of Accenture Ltd, the general
partner of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906
of the Sarbanes-Oxley Act of 2002, that:  (1)
    The Report fully complies with the requirements of Section 13(a) or 15(d)
of the Securities Exchange Act of 1934; and(2)
    The information contained in the Report fairly presents, in all material
respects, the financial condition and results of operations of the Company. Dated: January 7, 2005 /s/  Michael G. McGrath
Michael G. McGrathChief Financial Officer of Accenture Ltd,
the general partner of Accenture SCA
##### 



Exhibit 99.6 CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350 In connection with the Annual Report on Form 40-F of Extendicare Inc. (the
Company) for the year ended December 31, 2003 (the Report) each of the
undersigned officers of the Company certify solely for purposes of complying
with 18 U.S.C. § 1350, that:  (1)
    
    the Report fully complies with the requirements of section 13(a) or 15(d)
of the Securities Exchange Act of 1934; and(2)
    
    the information contained in the Report fairly presents, in all material
respects, the financial condition and results of operations of the
Company. /s/ Mel Rhinelander  
 /s/ Mark W. Durishan  
 A signed original of this written statement required by Section 906 has been
provided to Extendicare Inc. and will be retained by the Company and furnished
to the Securities and Exchange Commission or its staff upon request.
EXHIBIT 23.1






            CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM


We have issued our report dated March 4, 2005, accompanying the
consolidated financial statements included in the Annual Report of EP
MedSystems, Inc. and Subsidiaries on Form 10-KSB for the year ended December 31,
2004. We hereby consent to the incorporation by reference of said report in the
Registration Statements of EP MedSystems, Inc. and Subsidiaries on Forms S-8
(File No. 333-346656, effective April 13, 2000, amended June 29, 2000; File No.
333-122081, effective January 14, 2005) and Forms S-3 (File No. 333-104231,
effective April 21, 2003; File No. 333-110023, effective November 19, 2003, File
No. 333-112131, effective February 4, 2004; File No. 333-120263, effective
November 26, 2004 and File No. 333-122082, effective February 3, 2005 ).



/s/ Grant Thornton LLP

Philadelphia, Pennsylvania
March 4, 2005
<PAGE>

The Board of Directors
Bigmar, Inc.:

We consent to incorporation by reference in the registration statements on Form
S-3 (Nos. 333-92353, 333-640899, 333-43627) of Bigmar, Inc. of our report dated
March 30, 2000, relating to the consolidated balance sheets of Bigmar, Inc. and
subsidiaries as of December 31, 1999 and 1998, and the related consolidated
statements of operations, stockholders' equity, cash flows, and comprehensive
income (loss) for each of the years in the three-year period ended December 31,
1999, which report appears in the December 31, 1999, annual report on Form
10-KSB of Bigmar, Inc.

Our report dated March 16, 2000, contains an explanatory paragraph that states
that the Company has suffered recurring losses from operations and anticipates
it will require additional financing in order to fund its operations during
2001, which raise substantial doubt about its ability to continue as a going
concern. The consolidated financial statements do not include any adjustments
that might result from the outcome of that uncertainty.



Columbus, Ohio
March 30, 2000
Exhibit 31




CERTIFICATION




I, Joel Gardner, President, CEO, Principal Financial Officer and Principal Accounting Officer, certify that:




1. I have reviewed this quarterly report on Form 10-Q of Megola, Inc.;




2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;




3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;




4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and we have:




a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within the Corporation, particularly during the period in which this quarterly report is being prepared;




b) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and




c) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and




5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent function):




a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and




b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.




Date: June 20, 2011/s/ JOEL GARDNERJoel GardnerPresident, CEO, Principal Financial Officer and Principal Accounting Officer
## F IRST 

## D ISTRICT 

## C OURT OF 

## A PPEAL 

## S TATE OF 

## F LORIDA

_____________________________
No. 1D 18

- 1635

_____________________________
M ICHAEL J OHNSON , Appellant,

v.

S TATE OF F LORIDA , Appellee.

_____________________________ On appeal from the Circuit Court for W ashington County

. Timothy Register , Judge

. April 11, 2019

P ER C URIAM

.
A FFIRMED

.
M AKAR , W INOKUR , and M.K. T HOMAS , JJ., concur.

_____________________________ Not final until disposition of any timely and authorized motion under Fla. R. App. P. 9.330 or 9.331

.

_____________________________

Michael Johnson, pro se
, Appellant.

Ashley Moody , Attorney General, Tallahassee
, for Appellee.
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Advisory Council on Historic Preservation

# AGENCY:

Advisory Council on Historic Preservation.

# ACTION:

Notice of performance review board.

# SUMMARY:

Appointment of individuals to serve as members of the Performance Review Board.

# DATES:

These appointments are applicable on January 22, 2024.

# FOR FURTHER INFORMATION CONTACT:

                        Javier E. Marqués, General Counsel, Advisory Council on Historic Preservation,                         *jmarques@achp.gov;*                         202-517-0192.                    

# SUPPLEMENTARY INFORMATION:

The Chair of the Advisory Council on Historic Preservation (ACHP) has appointed the following individuals to serve on the ACHP's Performance Review Board (PRB):

*Chairperson of the PRB:*                         Kristopher B. King                    

*Member*                        —Dr. Teresa R. Pohlman                    

*Member*                        —Joy Beasley                    

*Authority:*5 U.S.C. 4314(c)(4).                

Dated: January 22, 2024.

Javier E. Marqués,

General Counsel.

[FR Doc. 2024-01476 Filed 1-24-24; 8:45 am]

BILLING CODE 4310-K6-P
EXHIBIT 99.1

SERVICER'S ANNUAL STATEMENT 
OF COMPLIANCE




March 13, 1997

VIA CERTIFIED MAIL
RETURN RECEIPT REQUESTED

LaSalle National Bank
135 South LaSalle Street
Suite 1740
Chicago, Illinois  60603
Attention:  Asset Backed Securities Trust Services -- Nomura Mega 5

Ladies & Gentlemen:

Reference is made to the Pooling and Servicing Agreement dated as of 
April 1, 1996, among Nomura Asset Securities Corporation, as Depositor,  
AMRESCO Management, Inc., ("AMRESCO") as Servicer, LaSalle National 
Bank, as Trustee, and ABN AMRO Bank, N.V., as Fiscal Agent, entered into 
in connection with Nomura Asset Securities Corporation Commercial 
Mortgage Pass-Through Certificates, Series 1996-MDV (the "PSA").

As Senior Vice President of AMRESCO, I have delegated to specified 
officers ("Officers") the responsibility for reviewing and monitoring 
the activities of AMRESCO, and of our performance under the PSA.

Accordingly, pursuant to the terms of Section 3.14 of the PSA and in 
accordance with certifications made to me by each of the Officers, 
AMRESCO certifies the following:

(1) A review of the activities of AMRESCO for the period from April 1, 
1996 to December 31, 1996, and of its performance under this PSA has 
been made under the supervision of the Officers, who have in turn 
been under my supervision;

(2) To the best of my knowledge and the Officers' knowledge, based on 
such review, AMRESCO has fulfilled its obligations as Servicer in all 
material respects under the PSA throughout the period from April 1, 
1996 to December 31, 1996;

(3) No Subservicers were used by AMRESCO with respect to its duties under 
this PSA during the period from April 1, 1996 to December 31, 1996; 
and

<PAGE>

LaSalle National Bank
March 13, 1997
Page 2


(4) To the best of my knowledge and the Officers' knowledge,  AMRESCO has 
not received any notice regarding the qualification, or challenging 
the status, of the Series 1996-MDV Upper-Tier REMIC or Lower-Tier 
REMIC as a REMIC from the Internal Revenue Service or any other 
governmental agency or body.

Please refer to the enclosed independent accountants' report dated 
February 7, 1997, delivered pursuant to Section 3.15 of the PSA, which 
discusses the results of their review of our activities under this PSA 
and which is incorporated herein by reference.

Very truly yours,


/s/ Daniel B. Kirby

Daniel B. Kirby
Senior Vice President
AMRESCO Management, Inc.


Enclosures

cc:     Nomura Asset Securities Corporation
2 World Financial Center
Building B, 21st Floor
New York, New York  10281-1198
Attention:      Perry Gershon
Sheryl McAfee

Duff & Phelps Credit Rating Co.
55 East Monroe Street, 35th Floor
Chicago, Illinois  60603
Attention: Structured Finance-
Commercial Real Estate Monitoring

Fitch Investors Service, L.P.
One State Street Plaza
New York, New York  10004
Attention: Commercial Mortgage Surveillance

<PAGE>

LaSalle National Bank
March 13, 1997
Page 3


Enclosures

cc:     Standard & Poor's Ratings Services
25 Broadway
New York, New York  10004
Attention: Commercial Mortgage Surveillance

Cadwalader, Wickersham & Taft
100 Maiden Lane
New York, NY  10038
Attention:  Anna H. Glick, Esq.
Exhibit 10.5






EXHIBIT 11







SUMMARY OF OFFICER AND DIRECTOR COMPENSATION












The Employment Agreement in Exhibits 7 & 8 of this report is the only written contractual compensation arrangement the Company has with any of its directors and Executive Officers.







During 2017, the Company's Chief Executive and Principal Financial Officers (the Company's "Named Executive Officers") are scheduled to receive the following compensation from the Company:


 


	
Compensation Arrangement

	
2017 Scheduled Amount


	 	 
	
Base salary

	
$  156,000 (CEO); $117,100 (PFO)


	
401(k) matching contributions

	
        6,480 (maximum)


	
Section 125 plan matching contributions (1)

	
           600 (maximum)


	
Management bonus

	
will be determined at year-end


	
Pet health benefits (1)

	
           500 (maximum)


	
Family medical benefits (1)

	
will depend on future events


	
Travel expense reimbursement (2)

	
       30,000 (CEO); 500 (PFO)





 


During 2017, the Company's Directors are scheduled to receive the following compensation from the Company:







	
Compensation Arrangement

	 	
Ernst Hoyer

	 	 	
Barbara Payne

	 	 	
James Beeson

	 
	
Base

	 	
$

	
25,000

	 	 	
$

	
25,000

	 	 	
$

	
25,000

	 
	
Executive Committee

	 	 	
4,000

	 	 	 	
-

	 	 	 	
-

	 
	
Audit Committee Chairman

	 	 	
3,000

	 	 	 	
-

	 	 	 	
-

	 
	
Travel Expense Reimbursement (2)

	 	 	
500

	 	 	 	
700

	 	 	 	
500

	 








	
(1)

	
  CEO and PFO participate on the same basis as other eligible employees.


	 	 
	
(2)

	
 Estimated 2017 travel expenses on behalf of UTMD business.  The Company reimburses its employees and directors for authorized business expenses.